KR102714111B1 - 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 - Google Patents

사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 Download PDF

Info

Publication number
KR102714111B1
KR102714111B1 KR1020237031201A KR20237031201A KR102714111B1 KR 102714111 B1 KR102714111 B1 KR 102714111B1 KR 1020237031201 A KR1020237031201 A KR 1020237031201A KR 20237031201 A KR20237031201 A KR 20237031201A KR 102714111 B1 KR102714111 B1 KR 102714111B1
Authority
KR
South Korea
Prior art keywords
human
mouse
polypeptide
chimeric
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237031201A
Other languages
English (en)
Korean (ko)
Other versions
KR20230135166A (ko
Inventor
린 맥도날드
앤드류 제이. 머피
낙신 투
베라 보로니나
케이건 규레르
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020247032785A priority Critical patent/KR20240147707A/ko
Publication of KR20230135166A publication Critical patent/KR20230135166A/ko
Application granted granted Critical
Publication of KR102714111B1 publication Critical patent/KR102714111B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
KR1020237031201A 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 Active KR102714111B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247032785A KR20240147707A (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361766762P 2013-02-20 2013-02-20
US61/766,762 2013-02-20
US201361890915P 2013-10-15 2013-10-15
US61/890,915 2013-10-15
KR1020227006387A KR102579405B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
PCT/US2014/017395 WO2014130671A1 (en) 2013-02-20 2014-02-20 Mice expressing humanized t-cell co-receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006387A Division KR102579405B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032785A Division KR20240147707A (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스

Publications (2)

Publication Number Publication Date
KR20230135166A KR20230135166A (ko) 2023-09-22
KR102714111B1 true KR102714111B1 (ko) 2024-10-11

Family

ID=50236327

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237031201A Active KR102714111B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020247032785A Pending KR20240147707A (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020217032326A Active KR102369454B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020157025675A Active KR102313047B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020227006387A Active KR102579405B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020247032785A Pending KR20240147707A (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020217032326A Active KR102369454B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020157025675A Active KR102313047B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
KR1020227006387A Active KR102579405B1 (ko) 2013-02-20 2014-02-20 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스

Country Status (19)

Country Link
US (4) US9848587B2 (cg-RX-API-DMAC7.html)
EP (3) EP2958938B1 (cg-RX-API-DMAC7.html)
JP (5) JP6444895B2 (cg-RX-API-DMAC7.html)
KR (5) KR102714111B1 (cg-RX-API-DMAC7.html)
CN (2) CN105164153B (cg-RX-API-DMAC7.html)
AU (4) AU2014218897C1 (cg-RX-API-DMAC7.html)
CA (1) CA2900832A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121979T1 (cg-RX-API-DMAC7.html)
DK (1) DK2958938T3 (cg-RX-API-DMAC7.html)
ES (2) ES2736052T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191280T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045478T2 (cg-RX-API-DMAC7.html)
LT (1) LT2958938T (cg-RX-API-DMAC7.html)
PL (1) PL2958938T3 (cg-RX-API-DMAC7.html)
PT (1) PT2958938T (cg-RX-API-DMAC7.html)
RS (1) RS58962B1 (cg-RX-API-DMAC7.html)
SI (1) SI2958938T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900429T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014130671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
LT3262932T (lt) 2011-10-28 2019-08-26 Regeneron Pharmaceuticals, Inc. Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SMT201900429T1 (it) * 2013-02-20 2019-09-09 Regeneron Pharma Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
DK4269430T3 (da) 2013-09-23 2025-08-18 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
RS63410B1 (sr) * 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
LT3230320T (lt) * 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
DK3280257T3 (da) * 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
WO2017150763A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 인간 cd3 발현 동물모델 및 이의 용도
EP3462853B1 (en) 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
AU2018375796B2 (en) 2017-11-30 2024-11-21 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
AU2019242586B2 (en) 2018-03-26 2025-09-11 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
MA52536A (fr) 2018-04-19 2021-02-24 Baylor College Medicine Reprogrammation de lymphocytes t cd4 en lymphocytes cd8 cytotoxiques par expression forcée de récepteurs de lymphocytes t restreints à cd8ab et de classe 1
PL3823443T3 (pl) 2018-07-16 2024-09-23 Regeneron Pharmaceuticals, Inc. Modele gryzoni z chorobą ditra i ich zastosowania
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
KR20250077529A (ko) 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs
GB202405657D0 (en) 2024-04-22 2024-06-05 T Therapeutics Ltd T cell receptor identification and provision

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524841A (ja) 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
US20050066375A1 (en) * 2001-07-13 2005-03-24 Kader Thiam Cell and transgenic animal modelling human antigenic presentation and their uses
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
WO2011023971A1 (en) 2009-08-27 2011-03-03 Budha Singh Dhinjan Wall bead
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2011100761A2 (en) 2010-02-15 2011-08-18 Indiana University Research And Technology Corporation Cd4 t-cells involved in mammalian host response to epithelial cell infection and uses thereof
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
US8084256B2 (en) 2001-05-15 2011-12-27 Ortho-Mcneil Pharmaceutical Corp. Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
US20030093818A1 (en) 2000-12-19 2003-05-15 Belmont Heather J. Transgenic animals comprising a humanized immune system
JP2006520604A (ja) * 2003-03-19 2006-09-14 アイソジェニス・インコーポレイテッド ＣＤ８α鎖に基づき免疫原性が減少した遺伝子治療ベクター
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
JP4857450B2 (ja) 2004-03-09 2012-01-18 財団法人名古屋産業科学研究所 ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
EP1778296B1 (en) * 2004-07-20 2012-06-06 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
US9277999B2 (en) * 2009-02-27 2016-03-08 University of Pittsburgh—of the Commonwealth System of Higher Education Joint bioscaffolds
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
LT3262932T (lt) 2011-10-28 2019-08-26 Regeneron Pharmaceuticals, Inc. Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
LT3590332T (lt) * 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT201900429T1 (it) * 2013-02-20 2019-09-09 Regeneron Pharma Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2014164640A1 (en) 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
JP6456350B2 (ja) 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
JP7172900B2 (ja) * 2019-07-26 2022-11-16 株式会社デンソー 走行中給電システム

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
JP2004524841A (ja) 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
US8084256B2 (en) 2001-05-15 2011-12-27 Ortho-Mcneil Pharmaceutical Corp. Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
US20050066375A1 (en) * 2001-07-13 2005-03-24 Kader Thiam Cell and transgenic animal modelling human antigenic presentation and their uses
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
JP2012021004A (ja) 2008-04-11 2012-02-02 Chugai Pharmaceut Co Ltd 複数分子の抗原に繰り返し結合する抗原結合分子
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
WO2011023971A1 (en) 2009-08-27 2011-03-03 Budha Singh Dhinjan Wall bead
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2011100761A2 (en) 2010-02-15 2011-08-18 Indiana University Research And Technology Corporation Cd4 t-cells involved in mammalian host response to epithelial cell infection and uses thereof
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Curr Opin Immunol.vol.20 no.4 pp.460-470, 2008.
Exp Med. vol.173 no.4 pp.1007-1015, 1991.
J Biol Chem., vol.285 no.13 pp.9327-9338, 2010.
J Thromb Haemost. Suppl 1 pp.92-97, 2009.
J. Mol. Biol. vol.270 no.4 pp.587-597, 1997.
Nature Biotechnology, Vol. 28, No. 11, pp 1203-1207, 2010.

Also Published As

Publication number Publication date
SMT201900429T1 (it) 2019-09-09
US10820581B2 (en) 2020-11-03
EP3543253A1 (en) 2019-09-25
LT2958938T (lt) 2019-07-25
US20140245466A1 (en) 2014-08-28
EP2958938B1 (en) 2019-04-17
CN105164153A (zh) 2015-12-16
JP6752842B2 (ja) 2020-09-09
AU2021290271A1 (en) 2022-01-27
SI2958938T1 (sl) 2019-08-30
US9848587B2 (en) 2017-12-26
AU2014218897C1 (en) 2019-03-07
KR102313047B1 (ko) 2021-10-19
KR20230135166A (ko) 2023-09-22
ES2736052T3 (es) 2019-12-23
AU2025200206A1 (en) 2025-01-30
KR102579405B1 (ko) 2023-09-18
EP2958938A1 (en) 2015-12-30
US20250000070A1 (en) 2025-01-02
AU2018271383B2 (en) 2022-01-20
CN111484999B (zh) 2024-10-25
EP3543253C0 (en) 2024-03-27
AU2018271383A1 (en) 2018-12-20
JP7261772B2 (ja) 2023-04-20
PL2958938T3 (pl) 2019-11-29
CA2900832A1 (en) 2014-08-28
AU2014218897A1 (en) 2015-09-10
US20210068378A1 (en) 2021-03-11
DK2958938T3 (da) 2019-07-15
CY1121979T1 (el) 2020-10-14
HRP20191280T1 (hr) 2019-10-18
HK1213908A1 (en) 2016-07-15
RS58962B1 (sr) 2019-08-30
KR20220028187A (ko) 2022-03-08
ES2987445T3 (es) 2024-11-14
PT2958938T (pt) 2019-07-23
KR20240147707A (ko) 2024-10-08
WO2014130671A8 (en) 2015-10-01
JP2016506761A (ja) 2016-03-07
KR20150119409A (ko) 2015-10-23
JP2023184695A (ja) 2023-12-28
JP2021000096A (ja) 2021-01-07
HUE045478T2 (hu) 2019-12-30
CN111484999A (zh) 2020-08-04
US12063915B2 (en) 2024-08-20
KR102369454B1 (ko) 2022-03-04
JP6444895B2 (ja) 2018-12-26
EP3543253B1 (en) 2024-03-27
EP4374690A3 (en) 2024-08-21
AU2014218897B2 (en) 2018-08-30
WO2014130671A1 (en) 2014-08-28
JP2018126169A (ja) 2018-08-16
JP2022121465A (ja) 2022-08-19
AU2021290271B2 (en) 2024-10-10
CN105164153B (zh) 2020-04-24
EP4374690A2 (en) 2024-05-29
KR20210124541A (ko) 2021-10-14
US20180084768A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
KR102714111B1 (ko) 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
RU2732628C2 (ru) Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
HUE035652T2 (en) Genetically modified major histocompatibility complex mice
KR20230164150A (ko) TCRβ 레퍼토리의 다양성이 개선된 인간화 세포 면역 시스템 성분을 포함하는 유전자 변형된 마우스
HK40111794A (en) Mice expressing humanized t-cell co-receptors
HK40013874A (en) Mice expressing humanized t-cell co-receptors
HK1213908B (en) Mice expressing humanized t-cell co-receptors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230912

Application number text: 1020227006387

Filing date: 20220224

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231025

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240628

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240930

Application number text: 1020227006387

Filing date: 20220224

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240930

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241002

End annual number: 3

Start annual number: 1

PG1601 Publication of registration